Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Creative Graphics Solutions India Ltd

| Q3 FY2026 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤14th Mar 26

Summary : Creative Graphics is aggressively expanding its flexography and pharma packaging capacities, targeting significant revenue growth despite commodity price volatility and working capital demands.

Management Perspective positive : "We are very, very enthusiastic about the new setup.""We are very, very hopeful that, this acquisition will give a different paradigm to our company's potential.""We are very bullish on the Alu-Alu business, and this also speaks to the previous question. We are bullish on the value business on the long term.""We expect the demand to continue strong. In any month, our order book has exceeded our supply capacity, which is why we have expanded the capacity.""We are getting a lot of traction in PVC and PDVC. A lot of export inquiries."

Concall Report Analysis & Insights

Business Overview

  1. Creative Graphics operates three segments: flexographic printing plates, pharmaceutical packaging (Wahren), and pre-media services (CG Premedia).
  2. The company started in 2001, diversified into pharma packaging in 2023, and listed on April 9th last year.
  3. Flexography is a sustainable printing process used for labels, flexible packaging, and corrugated boxes.
  4. Wahren, the pharma packaging arm, focuses on ALU-ALU foil, PVDC, PVC, and OSD drug packaging.
  5. CG Premedia provides mock-up and artwork solutions, including 3D CGI, to brand owners.

Future Growth Prospects

  1. Management targets doubling revenue annually, aiming for 1000+ crores annual turnover in a few years.
  2. New flexo units are commissioned in Oman and Bangalore, expanding geographic presence and market access.
  3. Wahren's ALU-ALU capacity is expanding from 8,000 to 20,000 tons, with commercial sales expected next year.
  4. New PVDC and tandem lines are commissioned, offering specialized products with higher realization and less competition.
  5. The company is actively pursuing export opportunities, especially for PVDC products in new markets like Nepal and Bangladesh.

Management Insights

  1. Deepanshu Goel stated the company has built a state-of-the-art infrastructure over 25 years for high-quality, timely delivery.
  2. Pulkit Agrawal noted the company achieved 51% CAGR last year and 68% CAGR in profits over the same period.
  3. Management is very bullish on the Alu-Alu and value businesses, expecting strong demand to continue.
  4. They anticipate EBITDA margins for ALU-ALU in low teens and flexography in high teens to low 20s.
  5. Management confirmed active discussions for arranging additional debt-focused working capital.

Signs of Skepticism

  1. Management declined to provide specific margin guidance due to VUCA world volatility.
  2. Passing on aluminum price changes is a "mix and match" situation, not always a complete pass-through.
  3. Specifics on working capital funding and interest burden for bill discounting were not fully disclosed.
  4. The 1000 crore turnover target lacks a clear timeline or CAGR rate from management.
  5. The company's ability to sustain current margins with increased low-margin product contribution is questioned.

Risk Factors

  1. Middle East conflict and rising oil prices create supply chain volatility and freight cost increases.
  2. Aluminum price volatility impacts margins, though the company aims to pass on costs.
  3. Significant working capital is required to support rapid growth and 90-day credit periods for pharma clients.
  4. Achieving 50% capacity utilization for new expansions presents a challenge.
  5. The company does not have long-term contracts, potentially increasing business risk.

Good To Know

  1. The company acquired Color Dot in Chennai (2017) and Digiflex in Baddi.
  2. Wahren acquired Italian European machine for ALU-ALU expansion.
  3. The company acquired PVC, PVDC, and tandem machines through NCLT at very low prices.
  4. Key clients include Emami, Tata Chemicals, Unilever, P&G, PepsiCo, Cadila, Ajanta, Zydus, and Macleods.
  5. The company uses preferred buyers like MacDermid, Kodak, Miracle, and Dupont.

Key Drivers

  1. New capacity commissioning in Oman, Bangalore.
  2. Wahren's ALU-ALU capacity expansion to 20,000 tons.
  3. New PVDC, tandem lines for specialized products.
  4. Strong export traction for PVDC in new markets.

Key Analyst Discussions

Market Trends & Consumer Behavior

  1. Analysts asked about oversupply in aluminum packaging and its impact on the industry.
  2. Management noted strong demand in the pharma sector and export traction for PVDC.
  3. Discussion on whether customers are shifting from Alu-Alu to PVDC due to cost differences.
  4. Management stated that product changes in pharma are slow due to stability requirements and chemical formulations.
  5. The overall OSB market is experiencing strong demand.

Financial Highlights

  1. Analysts questioned the impact of Middle East conflict on margins and the sustainability of current margin levels.
  2. Management expects 75-80% of pharma packaging revenue from Alu-Alu, PVC, PVDC, and tandem lines.
  3. Queries were raised on capacity utilization for FY27 (50% for Alu-Alu, 30-40% for PVDC).
  4. Analysts inquired about the revenue potential of Wahren (700-750 crores) and PVDC (200-250 crores).
  5. Questions about funding for 1000 crore target and working capital for 90-day credit periods were addressed.

Product Composition

  1. Questions about the products and revenue realization from the new tandem line.
  2. Management explained tandem lines enable specialized products like CR foils and contraceptive films.
  3. The new PVDC factory is expected to add 100 crore rupees per annum at full capacity.
  4. The company's multi-product offering helps attain customers better.
  5. The PVC market is connecting to PVDC, indicating strong demand for the combined offering.

Strategic Considerations

  1. Analysts asked about the timeline for achieving the 1000 crore turnover target.
  2. Questions on whether additional funds (equity/debt) are needed for growth.
  3. Inquiries about the company's strategy for managing working capital for large pharma clients with 90-day credit.
  4. Discussion on the status of bill discounting initiatives to manage working capital.
  5. Questions about the impact of new capacity on reducing fixed costs and improving margins.
Creative Graphics Solutions India Ltd (CGRAPHICS) Concall Report Analysis & Insights | Dhanarthi